Reduced Cardiotoxicity of Ponatinib-Loaded PLGA-PEG-PLGA Nanoparticles in Zebrafish Xenograft Model.
Author | Al-Thani, Hissa F |
Author | Shurbaji, Samar |
Author | Zakaria, Zain Zaki |
Author | Hasan, Maram H |
Author | Goracinova, Katerina |
Author | Korashy, Hesham M |
Author | Yalcin, Huseyin C |
Available date | 2022-06-12T08:09:21Z |
Publication Date | 2022-06-02 |
Publication Name | Materials |
Identifier | http://dx.doi.org/10.3390/ma15113960 |
Citation | Al-Thani, H.F.; Shurbaji, S.; Zakaria, Z.Z.; Hasan, M.H.; Goracinova, K.; Korashy, H.M.; Yalcin, H.C. Reduced Cardiotoxicity of Ponatinib-Loaded PLGA-PEG-PLGA Nanoparticles in Zebrafish Xenograft Model. Materials 2022, 15, 3960. https://doi.org/10.3390/ma15113960 |
Abstract | Tyrosine kinase inhibitors (TKIs) are the new generation of anti-cancer drugs with high potential against cancer cells' proliferation and growth. However, TKIs are associated with severe cardiotoxicity, limiting their clinical value. One TKI that has been developed recently but not explored much is Ponatinib. The use of nanoparticles (NPs) as a better therapeutic agent to deliver anti-cancer drugs and reduce their cardiotoxicity has been recently considered. In this study, with the aim to reduce Ponatinib cardiotoxicity, Poly(D,L-lactide-co-glycolide)-b-poly(ethyleneoxide)-b-poly(D,L-lactide-co-glycolide) (PLGA-PEG-PLGA) triblock copolymer was used to synthesize Ponatinib in loaded PLGA-PEG-PLGA NPs for chronic myeloid leukemia (CML) treatment. In addition to physicochemical NPs characterization (NPs shape, size, size distribution, surface charge, dissolution rate, drug content, and efficacy of encapsulation) the efficacy and safety of these drug-delivery systems were assessed in vivo using zebrafish. Zebrafish are a powerful animal model for investigating the cardiotoxicity associated with anti-cancer drugs such as TKIs, to determine the optimum concentration of smart NPs with the least side effects, and to generate a xenograft model of several cancer types. Therefore, the cardiotoxicity of unloaded and drug-loaded PLGA-PEG-PLGA NPs was studied using the zebrafish model by measuring the survival rate and cardiac function parameters, and therapeutic concentration for in vivo efficacy studies was optimized in an in vivo setting. Further, the efficacy of drug-loaded PLGA-PEG-PLGA NPs was tested on the zebrafish cancer xenograft model, in which human myelogenous leukemia cell line K562 was transplanted into zebrafish embryos. Our results demonstrated that the Ponatinib-loaded PLGA-PEG-PLGA NPs at a concentration of 0.001 mg/mL are non-toxic/non-cardio-toxic in the studied zebrafish xenograft model. |
Sponsor | Qatar University Student Grant (QUST-2-CHS-2020-11). Also, the authors would like to thank QU Scholarship, Qatar University for the financial support to publish this article. |
Language | en |
Publisher | MDPI |
Subject | PLGA Ponatinib cancer cardiotoxicity leukemia nanomedicine nanoparticle pre-clinical xenograft zebrafish |
Type | Article |
Issue Number | 11 |
Volume Number | 15 |
ESSN | 1996-1944 |
Files in this item
This item appears in the following Collection(s)
-
Biomedical Research Center Research [714 items ]
-
Biomedical Sciences [697 items ]
-
Pharmacy Research [1243 items ]